This company listing is no longer active
Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !
EPZM Aktienübersicht
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Epizyme, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.47 |
| 52 Week High | US$5.80 |
| 52 Week Low | US$0.41 |
| Beta | -0.42 |
| 1 Month Change | -0.68% |
| 3 Month Change | 182.37% |
| 1 Year Change | -72.78% |
| 3 Year Change | -89.29% |
| 5 Year Change | -89.54% |
| Change since IPO | -93.61% |
Aktuelle Nachrichten und Updates
Recent updates
Epizyme GAAP EPS of -$0.21, revenue of $27.5M
Aug 09Epizyme Acquisition By Ipsen: CVR Value
Jul 05Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates
May 16
Epizyme: Taking Advantage Of Recent Sell-Off
Nov 25Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?
Sep 14Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts
Aug 10Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge
Jun 22Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jun 08Epizyme gains as peer Constellation attracts sizable premium from MorphoSys
Jun 02Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%
Feb 25Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jan 16
Epizyme says Boehringer terminates collaboration agreement
Dec 24Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?
Dec 12Epizyme Q3 2020 Earnings Preview
Nov 05Aktionärsrenditen
| EPZM | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -3.3% | -1.6% | -0.2% |
| 1Y | -72.8% | 7.4% | 25.6% |
Rendite im Vergleich zur Industrie: EPZM underperformed the US Biotechs industry which returned -23% over the past year.
Rendite vs. Markt: EPZM underperformed the US Market which returned -11.7% over the past year.
Preisvolatilität
| EPZM volatility | |
|---|---|
| EPZM Average Weekly Movement | 19.9% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stabiler Aktienkurs: EPZM's share price has been volatile over the past 3 months.
Volatilität im Zeitverlauf: EPZM's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2007 | 250 | Grant Bogle | www.epizyme.com |
Epizyme, Inc.'s Grundlagenzusammenfassung
| EPZM grundlegende Statistiken | |
|---|---|
| Marktanteil | US$247.50m |
| Gewinn(TTM) | -US$207.73m |
| Umsatz(TTM) | US$53.01m |
4.7x
Kurs-Umsatz-Verhältnis-1.2x
Kurs-Gewinn-VerhältnisIst EPZM zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| EPZM Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$53.01m |
| Kosten der Einnahmen | US$10.79m |
| Bruttogewinn | US$42.22m |
| Sonstige Ausgaben | US$249.95m |
| Umsatz | -US$207.73m |
Zuletzt gemeldete Gewinne
Jun 30, 2022
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -1.23 |
| Bruttomarge | 79.64% |
| Nettogewinnspanne | -391.88% |
| Schulden/Eigenkapital-Verhältnis | -1,148.4% |
Wie hat sich EPZM auf lange Sicht entwickelt?
Historische Performance und Vergleiche